title: Monitoring vital signs during infusion with infliximab does neither indicate nor predict development of acute infusion reactions.
authors.forename: Hilbert S
authors.initials: HS
authors.lastname: de Vries
authors.forename: Martijn G H
authors.initials: MG
authors.lastname: van Oijen
authors.forename: Karin E J
authors.initials: KE
authors.lastname: van Hoven-van Loo
authors.forename: Dirk J
authors.initials: DJ
authors.lastname: de Jong
mesh_terms: D000893:Anti-Inflammatory Agents / Q000009:adverse effects*; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D001794:Blood Pressure; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy*; D000069285:Infliximab; D007262:Infusions, Intravenous; D011237:Predictive Value of Tests; D011674:Pulse; D013696:Temperature; D014409:Tumor Necrosis Factor-alpha
chemical_list: D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab